Form 4: TherapeuticsMD Director Tommy G. Thompson Settles Restricted Stock Units

Director Tommy G. Thompson received 8,500 shares of TherapeuticsMD common stock upon settlement of restricted stock units on February 18, 2025.

Summary

• Tommy G. Thompson, a director of TherapeuticsMD, Inc., filed a Form 4 on February 20, 2025.
• On February 18, 2025, Thompson received 8,500 shares of common stock upon the settlement of restricted stock units (RSUs).
• The RSUs vested on July 17, 2024.
• Following the transaction, Thompson directly owns 14,454 shares of common stock.
• Thompson also indirectly owns shares through Thompson Family Holdings, LLC (21 shares) and Thompson Family Investments, LLC (14,312 shares).

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting a transaction. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates the change in Thompson's holdings of TherapeuticsMD stock.

Stakeholder Impact

• The transaction may have a minor impact on shareholders as it reflects an insider's activity in the company's stock.

Key Dates

Keywords

Form 4, TherapeuticsMD, Director, Tommy G. Thompson, Restricted Stock Units, TXMD, Beneficial Ownership, Common Stock